Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment
Year: 2021

&lt;b&gt;OBJECTIVE&lt;/b&gt; &lt;p&gt;Observational data associate greater prevalence of type 2 diabetes (T2D) with lower lipoprotein(a) levels. Whether pharmacologic lowering of lipoprotein(a) influences incident T2D is unknown. We determined the relationship of lipoprotein(a) concentration to incident T2D and effects of treatment with alirocumab, a PCSK9 inhibitor.&lt;/p&gt; &lt;p&gt;&lt;b&gt;RESEARCH DESIGN AND METHODS&lt;/b&gt;&lt;/p&gt; &lt;p&gt;The ODYSSEY OUTCOMES trial compared alirocuma